CA
NZ
UK
AU
IND
US
Vor Biopharma (NASDAQ:VOR) shares tumbled in Wednesday's session as the company presented its lead pipeline candidate telitacicept at a major virtual immunology and inflammation investor forum, with investors reassessing the drug's dual-indication development path and broader biotech risk profile following the presentation. The sharp …
Vistagen (NASDAQ:VTGN) shares are surging after the company reported preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. In an analysis of 322 subjects who continued into …
Eli Lilly (NYSE:LLY) shares are pulling back roughly 1% in Wednesday's session even as the underlying news flow around the company remains largely positive. CEO Dave Ricks said Lilly is capturing about 70% of new Medicare patients starting weight-loss drugs, a figure that points …
Merck (NYSE:MRK) shares are pulling back in Wednesday's session after a research firm downgraded the stock, arguing shares look overvalued and overbought following a strong rally dating back to mid-2025. The firm pointed to a trailing price-to-earnings ratio above 120 despite only mid-single-digitRevenuegrowth as …
Novo Nordisk (NYSE:NVO) shares are falling further in Wednesday's session as investors continue to digest the company's underwhelming 2030 strategy update from earlier this week. The stock remains under pressure following management's pipeline sales guidance of DKK150 billion by 2035 andRevenuegrowth targets in line …
Parabilis Medicines (NASDAQ:PBLS) shares are sliding further in Wednesday's session, extending a multi-day decline after last week's steep post-earnings selloff triggered by a much wider-than-expected quarterly loss of $2.32 per share against a consensus estimate of $0.16, on minimal revenue of $0.15 million. The …
Rapport Therapeutics (NASDAQ:RAPP) shares are sinking in Wednesday's session as investors book profits ahead of the closely watched Phase 2 bipolar mania readout for lead candidate RAP-219, despite a wave of bullish analyst commentary released the same day. One research firm reiterated a positive …
Inhibrx Biosciences (NASDAQ:INBX) shares are pulling back sharply in Wednesday's session, giving back a portion of the massive gains accumulated since April 2026, when reports first surfaced that Merck (NYSE:MRK) and Ono Pharmaceutical were exploring deals for the company's INBX-106 cancer program, potentially valued …
Kardigan (NASDAQ:KARD) shares are sharply lower in Wednesday's session, tumbling over 10% to trade near a 52-week low around $14.72, reversing a modest gain from earlier in the week. The sell-off comes despite recent commentary highlighting the company's decision to invest in and deliver …
Labcorp Holdings (NYSE:LH) shares are declining in Wednesday's session after the Centers for Medicare and Medicaid Services released preliminary 2027-2029 Clinical Laboratory Fee Schedule payment rates that the company warns would impose steep annual Medicare payment cuts on lab services, a change it argues …
Please wait processing your request...